Clinton Foundation Pens Agreement with Guava for Discounted CD4 Testing Tech
Guava Technologies said this week that the Clinton Foundation HIV/AIDS Initiative (CHAI) has signed an agreement with Guava designed to reduce the cost of CD4 testing for HIV patient monitoring by up to 50 percent.
Under the terms of the agreement, Guava will supply its Easy CD4 System at a discounted price to the members of CHAI’s Procurement Consortium, a coalition of 56 developing countries around the world including 27 African nations.
“Laboratory tests are a vital component of HIV/AIDS care and treatment,” President Bill Clinton said in a statement. “The success of treatment programs is dependent on the ability to diagnose and qualify HIV-positive patients for therapy and to monitor treatment efficacy and safety. We are pleased to work with Guava Technologies and commend them for helping to make HIV diagnostic equipment available at lower cost to members of our Procurement Consortium.”
The announcement follows news in May that Guava had received 510(k) clearance from the US Food and Drug Administration to sell its EZCD4 cellular analysis system for identifying and quantifying CD4+ lymphocytes in whole blood to monitor HIV-positive patients (see CBA News, 5/12/2006).
NIH Sets Aside $8M for Molecular Screening Assay Development in 2007
The National Institutes of Health plans to award $8 million in 2007 to investigators developing biological assays for automated high throughput molecular screening.
According to a request for applications issued last week, NIH will award up to 50 grants under the program, called "Assay Development for High Throughput Molecular Screening."
The RFA, a reissue of a program announced in 2005, is a component of the NIH Molecular Libraries and Imaging Roadmap Initiative.
The goal of the program is "to initiate a continuously evolving stream of scientifically and technologically outstanding assays that can be miniaturized, automated and further used for screening small molecules within the Molecular Libraries Screening Centers Network," NIH said.
NIH said that it will emphasize the screening of targets "for which an inadequate array of selective and potent small molecule modulators are available to the public."
Appropriate assays may include, but are not limited to: biochemical or cell-based assays of activity measuring target interactions involving small molecules, peptides, or other biological molecules; cell-based assays measuring cell signaling or the activity of biosynthetic pathways; assays of cellular or molecular phenotypes; modulation of gene expression, including effects on transcription, translation or RNA splicing; assays measuring protein-protein interactions; assays involving mutant proteins associated with disease; and assays using model organisms such as yeast, C. elegans, and zebrafish.
Letters of intent are due on Sept. 8 and applications are due Sept. 22.
Millipore Closes Serologicals Acquisition
Millipore this week said it has closed its $1.4 billion acquisition of Serologicals after that company's shareholders approved the deal last week.
The combined company will have approximately 5,800 employees, of whom more than 500 will work in R&D. Millipore's combined global field organization amounts to 1,200 people.
Millipore said in April it planned to buy Serologicals.